Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.

Published: 22nd March 2019

Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.


Use of neoadjuvant therapy in this study of 451 procedures increased the R0 resection rate (98.4 versus 92.1 per cent, P=0.002), and improved median overall survival from 66.5 to 100.1 months: hazard ratio 0.71, 95 per cent confidence interval 0.53 to 0.96, P=0.025.

Pubmed Link

Your comments